Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr 30:96–102. https://doi.org/10.1093/oxfordjournals.jncimonographs.a003469

Article  Google Scholar 

Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21(22):4165–4174. https://doi.org/10.1200/JCO.2003.12.005

Article  CAS  PubMed  Google Scholar 

Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455–1461. https://doi.org/10.1001/jama.2013.278932

Article  CAS  PubMed Central  PubMed  Google Scholar 

Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 33(3):258–264. https://doi.org/10.1200/JCO.2014.55.7827

Article  PubMed  Google Scholar 

Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS (2018) Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat 170(3):559–567. https://doi.org/10.1007/s10549-018-4801-3

Article  CAS  PubMed  Google Scholar 

von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804. https://doi.org/10.1200/JCO.2011.38.8595

Article  Google Scholar 

Fallahpour S, Navaneelan T, De P, Borgo A (2017) Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open 5(3):E734–E739. https://doi.org/10.9778/cmajo.20170030

Article  PubMed Central  PubMed  Google Scholar 

Masuda N, Lee SJ, Ohtani S et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147–2159. https://doi.org/10.1056/NEJMoa1612645

Article  CAS  PubMed  Google Scholar 

Von Minckwitz G, Huang CS, Mano MS et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617–628. https://doi.org/10.1056/NEJMoa1814017

Article  Google Scholar 

Gandhi S, Brackstone M, Hong NJL et al (2022) A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. Breast Cancer Res Treat 193(1):1–20. https://doi.org/10.1007/s10549-022-06522-6

Article  PubMed Central  PubMed  Google Scholar 

Korde LA, Somerfield MR, Carey LA et al (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39(13):1485–1505. https://doi.org/10.1200/JCO.20.03399

Article  CAS  PubMed Central  PubMed  Google Scholar 

Cardoso F, Kyriakides S, Ohno S et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(8):1194–1220. https://doi.org/10.1093/annonc/mdz173

Article  CAS  PubMed  Google Scholar 

NICE 2018. Early and locally advanced breast cancer: diagnosis and management. https://www.nice.org.uk/guidance/ng101 /resources/early-and-locally-advanced-breast-cancer-diagnosis- and-management-pdf-66141532914901.

Brezden-Masley C, Fathers KE, Coombes ME, Pourmirza B, Xue C, Jerzak KJ (2020) A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple-negative breast cancer. Cancer Med 9(20):7548–7557. https://doi.org/10.1002/cam4.3038

Article  CAS  PubMed Central  PubMed  Google Scholar 

Brezden-Masley C, Fathers KE, Coombes ME, Pourmirza B, Xue C, Jerzak KJ (2021) A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer. Breast Cancer Res Treat 185(3):807–815. https://doi.org/10.1007/s10549-020-05976-w

Article  CAS  PubMed  Google Scholar 

Mougalian SS, Soulos PR, Killelea BK et al (2015) Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer 121(15):2544–2552. https://doi.org/10.1002/cncr.29348

Article  PubMed  Google Scholar 

Mohiuddin JJ, Deal AM, Carey LA et al (2016) Neoadjuvant systemic therapy use for younger patients with breast cancer treated in different types of cancer centers across the United States. J Am Coll Surg 223(5):717-728.e4. https://doi.org/10.1016/j.jamcollsurg.2016.08.541

Article  PubMed Central  PubMed  Google Scholar 

Whitehead I, Irwin GW, Bannon F et al (2021) The NeST (Neoadjuvant systemic therapy in breast cancer) study: National practice questionnaire of United Kingdom multi-disciplinary decision making. BMC Cancer 21(1):90. https://doi.org/10.1186/s12885-020-07757-6

Article  CAS  PubMed Central  PubMed  Google Scholar 

Spronk PER, Volders JH, van den Tol P, Smorenburg CH, Vrancken Peeters MJTFD (2019) Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch breast cancer audit. Eur J Surg Oncol 45(2):110–117. https://doi.org/10.1016/j.ejso.2018.09.027

Article  PubMed  Google Scholar 

Benchimol EI, Smeeth L, Guttmann A et al (2015) The reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med 12(10):e1001885. https://doi.org/10.1371/journal.pmed.1001885

Article  PubMed Central  PubMed  Google Scholar 

Wodchis WP, Bushmeneva K, Nikitovic M, McKillop I (2013) Guidelines on person-level costing using administrative databases in Ontario.

Mittmann N, Seung S, Cheng S et al (2015) Generating costing algorithms for oncology drugs using administrative databases. Value in Health 18(7):A691. https://doi.org/10.1016/j.jval.2015.09.2568

Article  Google Scholar 

Mittmann N, Cheng SY, Liu N et al (2019) The generation of two specific cancer costing algorithms using Ontario administrative databases. Curr Oncol 26(5):e682–e692. https://doi.org/10.3747/co.26.5279

Article  CAS  PubMed Central  PubMed  Google Scholar 

Mavros MN, Coburn NG, Davis LE et al (2019) Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis. CMAJ 191(21):E574–E580. https://doi.org/10.1503/cmaj.190211

Article  PubMed Central  PubMed  Google Scholar 

Schroeder MC, Chapman CG, Nattinger MC et al (2016) Variation in geographic access to chemotherapy by definitions of providers and service locations: a population-based observational study. BMC Health Serv Res 16:274. https://doi.org/10.1186/s12913-016-1549-5

Article  PubMed Central  PubMed  Google Scholar 

Elixhauser A, Steiner C, Harris DR, Coffey RM (1998) Comorbidity measures for use with administrative data. Med Care 36(1):8–27. https://doi.org/10.1097/00005650-199801000-00004

Article  CAS  PubMed  Google Scholar 

Kralji B (2000) Measuring, “rurality” for purposes of health-care planning: an empirical measure for Ontario. Ont Med Rev 67:33–52

Google Scholar 

Health Quality Ontario. Geographic Location Methods Review: Summary Report. https://www.hqontario.ca/Portals/0/documents/pr/hqo-geographic-location-methods-review-report.pdf.

Matheson FI, Moloney G, van Inge T. 2016 Ontario Marginalization Index User Guide.

Tøge AG, Bell R (2016) Material deprivation and health: a longitudinal study. BMC Public Health 16:747. https://doi.org/10.1186/s12889-016-3327-z

Article  PubMed Central  PubMed  Google Scholar 

Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (2010) AJCC Cancer Staging Manual. 7th ed. Springer.

Hortobagyi G, Connolly J. AJCC Cancer Staging Manual (2016) 8th ed. (Amin M, Edge S, Greene F, et al, eds.) Springer International Publisher.

Cancer Care Ontario: Regional Cancer Centres https. https://www.cancercareontario.ca/en/find-cancer-services/regional-cancer-centres/list.

Austin PC (2009) Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 38(6):1228–1234. https://doi.org/10.1080/03610910902859574

Article  Google Scholar 

Ballinger GA (2004) Using generalized estimating equations for longitudinal data analysis. Organ Res Methods 7(2):127–150. https://doi.org/10.1177/1094428104263672

Article  Google Scholar 

Riedel F, Hoffmann AS, Moderow M et al (2020) Time trends of neoadjuvant chemotherapy for early breast cancer. Int J Cancer 147(11):3049–3058. https://doi.org/10.1002/ijc.33122

Article  CAS  PubMed  Google Scholar 

Powis M, Groome P, Biswanger N et al (2019) Cross-Canada differences in early-stage breast cancer treatment and acute-care use. Curr Oncol 26(5):624–639. https://doi.org/10.3747/co.26.5003

Article  Google Scholar 

Yee EK, Coburn NG, Zuk V et al (2021) Geographic impact on access to care and survival for non-curative esophagogastric cancer: a population-based study. Gastric Cancer 24(4):790–799. https://doi.org/10.1007/s10120-021-01157-w

Article  CAS  PubMed  Google Scholar 

Yee EK, Coburn NG, Davis LE et al (2020) Impact of geography on care delivery and survival for noncurable pancreatic adenocarcinoma: a population-based analysis. J Natl Compr Canc Netw 18(12):1642–1650. https://doi.org/10.6004/jnccn.2020.7605

Article  PubMed  Google Scholar